TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03986047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal care
Description: Wearing of a light elastic lower back heating wrap, which heats up to 40°C within 30 minutes and maintains this temperature continuously for 8 hours. Heat wrap will be worn during the day for 8 hours on 7 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: In addition of exercises performed with the physiotherapist at the first session, exercises will be performed at home five times over the next 7 days, for approximately 30 minutes each performing day. Three different categories of exercises will be given: 1) Functional activities exposure (sitting, sit-to-stand, lifting, bending, etc.); 2) cognitive contraction of trunk muscles and basic trunk motor control exercises; 3) mobility of the lumbar spine and preferential direction of movement. Exercises will be chosen and adapted for each participant by a physiotherapist, in function of pain presentation and intensity, and response to exercises.
Study: NCT02099058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: It is administered orally everyday.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: It is an intravenous infusion administered every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin
Description: It is administered by infusion in 21-day dosing cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin
Description: It is administered by infusion in 21-day dosing cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin
Description: It is administered by infusion in 28-day dosing cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin
Description: It is administered by infusion in 28-day dosing cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin
Description: It is administered by infusion in 28-day dosing cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin
Description: It is administered by infusion in 28-day dosing cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: It is administered orally everyday.
Study: NCT00482911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 25-50 mg by mouth once daily on days 1-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 25-50 mg by mouth once daily on days 1-28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 10 mg by mouth once daily on days 1-28.
Study: NCT03986047

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The same lower back wrap as the Thermal care group will be used, but cooled down to room temperature (opened in advance). The wrap will be worn following the same parameters (duration, frequency) than the Thermal care group.
Study: NCT00482911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: 12.5 - 25 mg by mouth once daily on days 1-28.
Study: NCT01741168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TLSO
Description: Patients in the TLSO arm will remain on bed rest until fitted with a TLSO. They will wear the TLSO for 8-10 weeks and mobilized in the brace by a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Orthosis
Description: Patients in the No Orthosis group will be mobilized immediately as tolerated by a physiotherapist with restrictions to limit bending or rotating through their trunk. They will be encouraged to return to normal activities after 8 weeks.
Study: NCT04060186

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloninflation
Description: Patient will inflate into a ballon made by a handglove 2-3times/h from 8:00-20:00 after evacuation of chronic subdural hematoma.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Balloninflation
Description: Patient will inflate into a ballon made by a handglove 2-3times/h from 8:00-20:00 after evacuation of chronic subdural hematoma.
Study: NCT02523300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEVAR
Description: The patients will be undertaken TEVAR

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TEVAR
Description: The patients will be undertaken TEVAR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: The other 120 patients will be given saline as control group
Study: NCT01384903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-3357
Description: Intravenous infusion once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma-derived antithrombin
Description: Intravenous infusion once a day
Study: NCT00990925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Lifestyle Modification Group
Description: Manualized group treatment to educate about basic nutritional concepts to help improve eating choices with the goal of losing weight.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Care as usual
Study: NCT03853889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: USG guided ONSD measurement preepidural
Description: Measurement of the diameter of the optic nerve sheath preepidural and postepidural anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG guided ONSD measurement preepidural
Description: Measurement of the diameter of the optic nerve sheath preepidural and postepidural anesthesia
Study: NCT03986047

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Education for the management of acute low back pain
Description: Participants will receive education on the management of acute low back pain by a physiotherapist . The main topics addressed will be patient reassurance, staying active, avoiding bed rest, activity modification, and sitting and bed postures/transfer. Participants will received a document that details advices covered during the session and the physiotherapist will answer any questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education for the management of acute low back pain
Description: Participants will receive education on the management of acute low back pain by a physiotherapist . The main topics addressed will be patient reassurance, staying active, avoiding bed rest, activity modification, and sitting and bed postures/transfer. Participants will received a document that details advices covered during the session and the physiotherapist will answer any questions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education for the management of acute low back pain
Description: Participants will receive education on the management of acute low back pain by a physiotherapist . The main topics addressed will be patient reassurance, staying active, avoiding bed rest, activity modification, and sitting and bed postures/transfer. Participants will received a document that details advices covered during the session and the physiotherapist will answer any questions.
Study: NCT02045914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calcium ionophore solution
Description: After microinjection of sperm into the oocyte, oocytes are incubated for 15 minutes in a 30 microlitre droplet of calcium ionomycin solution
Study: NCT04815135

Intervention type: OTHER
Intervention: Observational study
Description: Observational study, the study did not involve any interventions
Study: NCT03283150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the bispectral index (BIS) values to normalize to awake level for the MER.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
Study: NCT03125811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Isopropyl Alcohol (IPA)
Description: Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Dissolvable Tablet Zofran (ondansetron)
Description: Single dose 4 mg tablet at 0 minutes.
Study: NCT04118569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Intervention
Description: Research staff conducts an open-ended, audio-recorded interview with the patient about their illness and how this illness has affected their psycho-social-spiritual well-being. The investigators will use the interview transcription to create a meta-narrative, which is then uploaded to the electronic medical record and the patient's primary nurse is notified that it is available to read.
Study: NCT01186640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
Description: I. First treatment phase: Chemoimmunotherapy A-FMC~Alemtuzumab:~Cycle 1+2:~10 mg s.c., days 1-3~Cycle 3+4:~CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
Study: NCT03667846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Generic topiramate, FDA-approve for clinical use, will be purchased in 25mg, 50mg, and 100mg strengths, and encapsulated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be encapsulated in identical capsules.
Study: NCT02258529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 tablets administered orally twice daily

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
Study: NCT01123473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Study: NCT02522091

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychology tests

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychology tests
Study: NCT01123473

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Study: NCT02699268

Intervention type: OTHER
Intervention: Lung function measurement
Description: The infants will be exposed to lung function measurements performed by a new metod (Volusense Pediatrics) and a validated method (EcoMedics Exhalyzer D). The two Methods will be compared. This is not an intervential study, but a study aiming to validate a New Method versus an old method
Study: NCT02679365

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower segment cesarean section and double lock closure of rectus sheath

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lower segment cesarean section and continuous non-locking closure of rectus sheath
Study: NCT02398695

Intervention type: OTHER
Intervention: Oral Samples
Description: Oral samples of saliva, dental plaque and DNA will be collected between the two groups.

Intervention type: OTHER
Intervention: Oral Samples
Description: Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
Study: NCT04343014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Root Retractor
Description: Fibroptic endutracheal intubation will be performed with tongue root retractor.
Study: NCT00299507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 30 mg/mL
Description: One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 30 mg/mL
Description: One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 60 mg/mL
Description: One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
Study: NCT04343014

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fibroscope
Description: Fibroptic endutracheal intubation will be performed in conventional way.
Study: NCT03033563

Intervention type: PROCEDURE
Intervention: Intracytoplasmic sperm injection
Description: Intracytoplasmic sperm injection
Study: NCT02481713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: motivational interviewing

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: learning style interviews
Description: interview and feedback about learning style
Study: NCT01038713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biliary stent placement
Description: Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biliary stent placement
Description: Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biliary stent placement
Description: Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biliary stent placement
Description: Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biliary stent placement
Description: Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.
Study: NCT02074072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 15 degree left-lateral tilt wedges
Description: The wedges are made of aluminium

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 15 degree left-lateral tilt wedges
Description: The wedges are made of aluminium

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 15 degree left-lateral tilt wedges
Description: The wedges are made of aluminium

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 degree left-lateral tilt wedges
Description: The wedges are made of aluminium

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 degree left-lateral tilt wedges
Description: The wedges are made of aluminium
Study: NCT02114528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic Drug Therapy
Description: Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Ventricular tachycardia catheter ablation.
Study: NCT02444611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG Vaccine
Description: intradermal vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG Vaccine
Description: intradermal vaccination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine
Description: intramuscular vaccination
Study: NCT00333866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 600mg/day
Study: NCT02444611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine
Description: intramuscular vaccination
Study: NCT01098435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDC-0313 (ALKS 33)
Description: Capsules for daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing lactose and no active drug for daily oral administration
Study: NCT02074072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 degree left-lateral tilt wedges
Description: The wedges are made of aluminium
Study: NCT04367597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based Neuromuscular Electrical Stimulation (NMES) therapy
Description: A home-based NMES treatment applied by the subjects daily

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Home-based Neuromuscular Electrical Stimulation (NMES) therapy
Description: A home-based NMES treatment applied by the subjects daily
Study: NCT00690170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine and Nicotine
Description: 0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)
Study: NCT04375397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules were to be administered orally with water once daily. For participants who required nasogastric tube (NGT) placement while on study, capsules may have been administered by opening the capsules, mixing with water, and flushing down the NGT.
Study: NCT00333866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 450mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 300mg/day
Study: NCT01694966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue MMX®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue MMX®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Methylene Blue MMX® tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
Study: NCT03459976

Intervention type: DIAGNOSTIC_TEST
Intervention: evaluate serum level HE4 in endometrial cancer
Description: 1. HE4 in beignin endometrial diseases~2. HE4 in endometrial cancer
Study: NCT00333866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02280772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucomannan

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT03806959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pan Capsule and colonoscopy in patients with IBS
Description: Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only Usual biological tests (CBC, CRP, TSH, anti-transglutaminase antibodies) and measurement of fecal calprotectin.
Study: NCT03134560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vein Display Instrument
Study: NCT03508817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 0.01% Eye Drops
Description: atropine eye drop in study eye once nightly for two years.
Study: NCT01838993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine inhalation
Description: Lidocaine inhalation before intubation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03628755

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Manipulation of Thyroid cartilage
Description: Digital manipulation of thyroid cartilage was applied to the anterior aspect of thyroid cartilage while using the thumb or finger and the patient was asked to speak.~prolongation of vowel is 7 to 8 seconds, voice rest after each set is 10 second.~total repetition is 60.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Manipulation of Thyroid cartilage
Description: Digital manipulation of thyroid cartilage was applied to the anterior aspect of thyroid cartilage while using the thumb or finger and the patient was asked to speak.~prolongation of vowel is 7 to 8 seconds, voice rest after each set is 10 second.~total repetition is 60.
Study: NCT01063361

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycemic index diet with pulses
Description: Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Cereal Fibre
Description: Subjects will be advised to follow a healthy high fibre diabetic diet.
Study: NCT03430726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt drink
Description: Food product; yogurt drink containing a multi-strain probiotic.